Should I buy or sell Tyra Biosciences stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tyra Biosciences in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TYRA shares. View TYRA analyst ratings or view top-rated stocks .

What is Tyra Biosciences' stock price target for 2024?

3 Wall Street research analysts have issued twelve-month price targets for Tyra Biosciences' shares. Their TYRA share price targets range from $15.00 to $28.00. On average, they expect the company's share price to reach $22.00 in the next twelve months. This suggests a possible upside of 46.9% from the stock's current price. View analysts price targets for TYRA or view top-rated stocks among Wall Street analysts .

How have TYRA shares performed in 2024?

Tyra Biosciences' stock was trading at $13.85 on January 1st, 2024. Since then, TYRA shares have increased by 8.2% and is now trading at $14.98. View the best growth stocks for 2024 here .

When is Tyra Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our TYRA earnings forecast .

How were Tyra Biosciences' earnings last quarter?

Tyra Biosciences, Inc. (NASDAQ:TYRA) posted its quarterly earnings results on Tuesday, March, 19th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.05.

When did Tyra Biosciences IPO?

Tyra Biosciences (TYRA) raised $100 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 6,700,000 shares at $14.00-$16.00 per share.

How do I buy shares of Tyra Biosciences?

Shares of TYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TYRA

Tyra Biosciences (TYRA) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free TYRA Stock Alerts

$14.98

+0.32 (+2.18%)

(As of 04/19/2024 ET)

Compare

Today's Range: $14.35
▼
$14.99
50-Day Range: $14.45
▼
$20.00
52-Week Range: $10.38
▼
$20.67

Volume: 216,071 shs
Average Volume: 132,300 shs
Market Capitalization: $786.75 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $22.00

Get Tyra Biosciences alerts:

Tyra Biosciences MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 46.9% Upside
$22.00 Price Target
Short Interest: Bearish
14.91% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$298,165 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.89) to ($2.42) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.67 out of 5 stars

Medical Sector

849th out of 911 stocks

Pharmaceutical Preparations Industry

386th out of 411 stocks

3.3

Analyst's Opinion

Consensus Rating
Tyra Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Tyra Biosciences has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
14.91% of the float of Tyra Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Tyra Biosciences has a short interest ratio ("days to cover") of 21, which indicates bearish sentiment.
Change versus previous month
Short interest in Tyra Biosciences has recently increased by 8.85%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Tyra Biosciences does not currently pay a dividend.
Dividend Growth
Tyra Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TYRA.

0.0

News and Social Media Coverage

Search Interest
Only 1 people have searched for TYRA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Tyra Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $298,165.00 in company stock.
Percentage Held by Insiders
18.40% of the stock of Tyra Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
84.14% of the stock of Tyra Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Tyra Biosciences are expected to decrease in the coming year, from ($1.89) to ($2.42) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Tyra Biosciences is -9.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Tyra Biosciences is -9.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Tyra Biosciences has a P/B Ratio of 3.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad American Alternative

Your Money is Not Safe

Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…

CLICK HERE TO GET YOUR GUIDE NOW

About Tyra Biosciences Stock (NASDAQ:TYRA)

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

TYRA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TYRA Stock News Headlines

March 26, 2024 | markets.businessinsider.com

Tyra Bioscience Poised for Growth: Buy Rating Affirmed Amid Promising Clinical Trials and Strategic Drug Development

March 19, 2024 | msn.com

TYRA Stock Earnings: Tyra Biosciences Misses EPS for Q4 2023

April 19, 2024 | American Alternative (Ad)

Your Money is Not Safe

March 19, 2024 | finance.yahoo.com

Tyra Biosciences Inc (TYRA) Reports Increased R&D Investments Amid Pipeline Progress

March 19, 2024 | msn.com

Tyra Biosciences files to sell 15.37M shares of common stock for holders

March 19, 2024 | finance.yahoo.com

Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights

March 6, 2024 | finance.yahoo.com

Insider Sell: Tyra Biosciences Inc (TYRA) COO Daniel Bensen Sells 9,152 Shares

March 1, 2024 | finance.yahoo.com

Insider Sell: Tyra Biosciences Inc (TYRA) COO Daniel Bensen Sells 8,644 Shares

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

February 27, 2024 | prnewswire.com

Tyra Biosciences to Present at Upcoming Investor Conferences

February 24, 2024 | msn.com

Tyra Biosciences (TYRA) Price Target Increased by 5.41% to 23.87

February 17, 2024 | finance.yahoo.com

TYRA Mar 2024 20.000 call

February 17, 2024 | finance.yahoo.com

TYRA Mar 2024 20.000 put

February 7, 2024 | finance.yahoo.com

Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference

February 7, 2024 | finance.yahoo.com

President and CEO Todd Harris Sells 100,000 Shares of Tyra Biosciences Inc (TYRA)

February 6, 2024 | msn.com

Tyra Bioscience Announces New Purchase Agreement

February 6, 2024 | msn.com

Tyra Bioscience Secures $200M for Clinical Drug Development

February 2, 2024 | nasdaq.com

Tyra Biosciences Climbs 23% After Announcing $200 Mln Private Placement

February 2, 2024 | marketwatch.com

Tyra Shares Jump After $200 Million Private Placement Funding

February 2, 2024 | msn.com

Tyra Biosciences spikes on $200M private financing

February 2, 2024 | finance.yahoo.com

Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing

February 1, 2024 | markets.businessinsider.com

Tyra : FDA Grants Rare Pediatric Disease Designation To TYRA-300 For Achondroplasia Treatment

February 1, 2024 | marketwatch.com

Tyra Biosciences Gets Rare Pediatric Disease Designation For Achondroplasia Therapy

February 1, 2024 | finance.yahoo.com

Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia

December 29, 2023 | realmoney.thestreet.com

Wedbush stays Outperform on Tyra Biosciences after pipeline updates

December 22, 2023 | finance.yahoo.com

Tyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300

December 16, 2023 | health.usnews.com

Tyra S. Carter

See More Headlines

Receive TYRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tyra Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/19/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:TYRA
CUSIP: N/A
CIK: 1863127
Web: www.tyra.bio
Phone: 619-728-4760
Fax: N/A
Employees: 49
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $22.00
High Stock Price Target: $28.00
Low Stock Price Target: $15.00
Potential Upside/Downside: +47.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.61)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-69,130,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -30.26%
Return on Assets: -28.53%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 13.81
Quick Ratio: 13.80

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.74 per share
Price / Book: 3.16

Miscellaneous

Outstanding Shares: 52,520,000
Free Float: 42,857,000
Market Cap: $786.22 million
Optionable: Optionable
Beta: 1.12

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Todd Harris Ph.D. (Age 45)
Co-Founder, President, CEO, Secretary, Treasurer & Director
Comp: $903.33k
Mr. Daniel Bensen (Age 48)
Co-Founder & COO
Comp: $630.8k
Mr. Ali D. Fawaz J.D.
General Counsel & Secretary
Mr. Alan Fuhrman (Age 67)
Chief Financial Officer
Dr. Robert L. Hudkins Ph.D. (Age 68)
Chief Technology Officer
Dr. Ronald V. Swanson Ph.D. (Age 60)
Chief Scientific Officer
Comp: $536.19k
Ms. Sarah Honig
Vice President of Corporate Development & Strategy
Dr. Hiroomi Tada M.D. (Age 59)
Ph.D., Chief Medical Officer
Comp: $519.65k
Dr. Piyush R. Patel Ph.D. (Age 58)
Chief Development Officer
Amy Conrad
Investor Contact

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TYRA Stock Analysis - Frequently Asked Questions

Should I buy or sell Tyra Biosciences stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tyra Biosciences in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TYRA shares.
View TYRA analyst ratings or view top-rated stocks.
What is Tyra Biosciences' stock price target for 2024?: 3 Wall Street research analysts have issued twelve-month price targets for Tyra Biosciences' shares. Their TYRA share price targets range from $15.00 to $28.00. On average, they expect the company's share price to reach $22.00 in the next twelve months. This suggests a possible upside of 46.9% from the stock's current price.
View analysts price targets for TYRA or view top-rated stocks among Wall Street analysts.
How have TYRA shares performed in 2024?: Tyra Biosciences' stock was trading at $13.85 on January 1st, 2024. Since then, TYRA shares have increased by 8.2% and is now trading at $14.98.
View the best growth stocks for 2024 here.
When is Tyra Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our TYRA earnings forecast.

How were Tyra Biosciences' earnings last quarter?: Tyra Biosciences, Inc. (NASDAQ:TYRA) posted its quarterly earnings results on Tuesday, March, 19th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.05.
When did Tyra Biosciences IPO?: Tyra Biosciences (TYRA) raised $100 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 6,700,000 shares at $14.00-$16.00 per share.
How do I buy shares of Tyra Biosciences?: Shares of TYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TYRA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial